natgillin/translations-raw huggingface dataset:
Rosiglitazone is a selective agonist at the PPAR (peroxisome proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of antihyperglycaemic agents.
Rosiglitazon je selektiven agonist za nuklearni receptor PPARγ (peroxisome proliferator activated receptor gamma) in sodi v tiazolidindionsko skupino antidiabetikov.
Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus: as monotherapy
Rosiglitazon je indiciran za zdravljenje sladkorne bolezni tipa 2: kot samostojno zdravilo
rosiglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces; glimepiride is a sulphonylurea: it stimulates the pancreas to produce more insulin.
rosiglitazon poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo insulin, ki ga proizvaja, bolje izrablja; glimepirid je sufonilsečnina: spodbuja trebušno slinavko, da proizvede več insulina.
rosiglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces; metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
rosiglitazon poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo insulin, ki ga proizvaja, bolje izrablja; metformin pa učinkuje predvsem tako, da zavira nastajanje glukoze in zmanjšuje njeno absorpcijo v črevesju.
Rosiglitazone monotherapy
Rosiglitazon kot monoterapija
Rosiglitazone monotherapy
Rosiglitazon kot samostojno zdravilo
Rosiglitazone should be discontinued if any deterioration in cardiac status occurs.
Če se stanje srca kakorkoli poslabša, je treba zdravljenje z rosiglitazonom prekiniti.
Rosiglitazone should not be used in patients with hepatic impairment.
Rosiglitazona bolniki z motnjami delovanja jeter ne smejo uporabljati.
Rosiglitazone with sulphonylurea
Rosiglitazon s sulfonilsečnino
rosuvastatin
(2,01-3,39)
Rosuvastatin
imvastatin
Rosuvastatin (10 mg single dose)
rosuvastatin (10 mg enkratni
Rosuvastatin (10 mg single dose)/ velpatasvir (100 mg once daily)d
Rosuvastatin (10 mg enkratni odmerek)/velpatasvir (100 mg enkrat na dan)d
Rosuvastatin (10 mg single dose)/Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)
rosuvastatin (10 mg enkratni odmerek)/elvitegravir (150 mg enkrat na dan odmerek)/kobicistat (150 mg enkrat na dan)
Rosuvastatin (10 mg single dose)/Elvitegravir (150 mg single dose)/Cobicistat (150 mg single dose)
rosuvastatin (10 mg enkratni odmerek)/elvitegravir (150 mg enkratni odmerek)/kobicistat (150 mg enkratni odmerek)
rosuvastatin (a medicine used to treat high cholesterol).
rosuvastatin (zdravilo, ki se uporablja za zdravljenje visokih ravni holesterola).
Rosuvastatin - used to lower cholesterol.
rosuvastatin – uporablja se za zmanjševanje koncentracije holesterola.
Rosuvastatin 10 mg QD
Rosuvastatin, 10 mg 1-krat na dan
Rosuvastatin 10 mg single dose (daclatasvir 60 mg once daily)
Rosuvastatin, enkratni 10-mg
rosuvastatin AUC 2.81 (2.34-3.37) ↑
AUC darunavirja 1,18 (1,11-1,25) 
Rosuvastatin AUC  2.08-fold Rosuvastatin Cmax  4.66-fold (Mechanism unknown)
Cmax rosuvastatina  4,66-krat. (Mehanizem ni znan.)
rosuvastatin Cmax 3.17 (2.57-3.91) ↑
Cmax ritonavirja 1,23 (1,14-1,32) 
Rosuvastatin Cmax ↑ 123% Rosuvastatin AUC ↑ 37% Rosuvastatin Cmin ↑ 6%
Cmax rosuvastatina ↑ 123% AUC rosuvastatina ↑ 37% Cmin rosuvastatina ↑ 6
rosuvastatin Cmin not studied
Cmin ritonavirja 1,44 (1,30-1,61) 
Rosuvastatin dose should not
Odmerek rosuvastatina ne sme biti
Rosuvastatin is largely excreted unchanged via the faeces, therefore interaction with efavirenz is not expected.
rosuvastatin v veliki meri izloči nespremenjen z blatom, ne pričakujemo interakcij z efavirenzem.
rosuvastatin is possible.
tatinom, je treba
rosuvastatin or other statins used to treat high cholesterol.
rosuvastatin ali druge statine, ki se uporabljajo za zdravljenje visokih ravni holesterola.
rosuvastatin or pravastatin (used to lower blood cholesterol) colchicine (used to treat gout flares with normal kidney and liver function).
rosuvastatina ali pravastatina (za zniževanje holesterola v krvi), kolhicin (za zdravljenje napadov protina pri bolnikih z normalnim ledvičnim in jetrnim delovanjem).
Rosuvastatin, 20 mg QD
Rosuvastatin, 20 mg enkrat na dan
Rosuvastatin, 20 mg QD
Telaprevir 750 mg trikrat na dan
Rosuvastatin, 20 mg QD
Vardenafil
rosuvastatin, a medicine used to lower cholesterol level;
rosuvastatin, zdravilo za zniževanje ravni holesterola v krvi.
rosuvastatin, atorvastatin, fluvastatin, simvastatin, pitavastatin or pravastatin, used to lower blood cholesterol oral contraceptives
rosuvastatin, atorvastatin, fluvastatin, simvastatin, pitavastatin ali pravastatin, ki se uporabljajo za zniževanje holesterola v krvi. peroralne kontraceptive.
rosuvastatin, fluvastatin, atorvastatin, medicines typically used to treat high cholesterol warfarin or phenprocoumon, medicines typically used to thin your blood
rosuvastatin, fluvastatin, atorvastatin, zdravila, ki se običajno uporabljajo za zdravljenje visokih vrednosti holesterola
rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol)
rosuvastatin, simvastatin, atorvastatin, pravastatin za hiperholesterolemijo (visok holesterol),
rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol)
rosuvastatin, simvastatin, atorvastatin, pravastatin za hiperholesterolemijo (zvišane vrednosti holesterola),
rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol)
rosuvastatin, simvastatin, atorvastatin, pravastatin za zdravljeje hiperholesterolemijo (zvišane vrednosti holesterola),
rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol) sulfasalazine for inflammatory bowel disease or rheumatoid arthritis
rosuvastatin, simvastatin, atorvastatin, pravastatin za hiperholesterolemijo (zvišane vrednosti holesterola),
Rosuvastatin/Tenofovir disoproxil fumarate
Zdravilne učinkovine po terapevtskih področjih
Rosuvastatin:
tadalafil:
Rosuvastatin:
Vardenafil:
Rosuvastatin: AUC: ↑ 38%
rosuvastatin: AUC: ↑ 38
Rotarix is supplied as a whitish powder in a single dose glass container and a separate oral applicator of solvent which contains a slow settling white deposit and a colourless supernatant.
Cepivo Rotarix je na voljo v enoodmerni steklenički z belkastim praškom in v ločenem z vehiklom napolnjenem peroralnem aplikatorju, ki vsebuje počasi usedajočo se belo usedlino in brezbarven supernatant.
Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live
Rotarix peroralna suspenzija v napolnjenem peroralnem aplikatorju Cepivo proti rotavirusom, živo
Rotarix oral suspension Rotavirus vaccine, live
Rotarix peroralna suspenzija Cepivo proti rotavirusom, živo
Rotarix should be administered with caution to individuals with immunodeficient close contacts, such as individuals with malignancies, or who are otherwise immunocompromised or individuals receiving immunosuppressive therapy.
Pri otrocih, ki so v tesnem stiku z osebami z imunsko pomanjkljivostjo, npr. osebami z rakavimi obolenji, s kakorkoli drugače oslabljenim imunskim sistemom ali osebami, ki se zdravijo z imunosupresivnimi zdravili, je potrebna previdnost pri cepljenju s cepivom Rotarix.
Rotate application sites with each new application.
Vsakič izberite drugo mesto nanosa.
Rotate infusion sites by choosing opposite sides of the body between future infusions.
Mesta infundiranja menjajte tako, da pri naslednji infuziji izberete mesto na nasprotni strani telesa.
Rotate injection site:
Krožno menjajte mesto injiciranja:
Rotateq is for oral administration only.
Cepivo RotaTeq je samo za peroralno uporabo.
RotaTeq is not indicated in this subset of paediatric population.
V tej podskupini pediatrične populacije cepivo RotaTeq ni indicirano.
RotaTeq may be given to infants who were born prematurely provided that the period of gestation was at least 25 weeks.
Cepivo RotaTeq lahko prejmejo nedonošenčki, ki so bili rojeni najmanj v 25. tednu nosečnosti.
RotaTeq – Pack size of 1 single-dose(2ml) Tube RotaTeq – Pack size of 10 single-dose(2ml) Tubes
RotaTeq – pakiranje z 1 eno-odmerno (2 ml) tubo RotaTeq – pakiranje z 10 eno-odmernimi (2 ml) tubami
RotaTeq, oral solution Rotavirus vaccine, live
RotaTeq peroralna raztopina cepivo proti rotavirusom, živo
Rotation Cycle 1: Upper left section of each area Rotation Cycle 2: Lower right section of each area Rotation Cycle 3: Middle left section of each area Rotation Cycle 4 Upper right section of each area Rotation Cycle 5: Lower left section of each area Rotation Cycle 6: Middle right section of each area
Rotacijski cikel 1: Zgornji levi del vsakega predela Rotacijski cikel 2: Spodnji desni del vsakega predela Rotacijski cikel 3: Srednji levi del vsakega predela Rotacijski cikel 4: Zgornji desni del vsakega predela Rotacijski cikel 5: Spodnji levi del vsakega predela Rotacijski cikel 6: Srednji desni del vsakega predela
Rotation of injection sites usually helps to effectively manage these reactions.
Menjavanje mesta injiciranja običajno pomaga pri učinkovitem obvladovanju teh reakcij.
ROTATION SCHEDULE
NAČRT MENJAVANJA MEST INJICIRANJA
Rotation schedule
Načrt izmeničnega injiciranja
ROTATION SCHEDULE:
NAČRT MENJAVANJA MEST INJICIRANJA
Rotation Schedule:
Načrt menjavanja mest injiciranja
rotavirus type* G1 not less than 2.2 x 106 IU1, 2 rotavirus type* G2 not less than 2.8 x 106 IU1, 2 rotavirus type* G3 not less than 2.2 x 106 IU1, 2 rotavirus type* G4 not less than 2.0 x 106 IU1, 2 rotavirus type* P1A[8] not less than 2.3 x 106 IU1, 2
rotaviruse tipa* G1 ne manj kot 2,2 x 106 i.e.1, 2 rotaviruse tipa* G2 ne manj kot 2,8 x 106 i.e.1, 2 rotaviruse tipa* G3 ne manj kot 2,2 x 106 i.e.1, 2 rotaviruse tipa* G4 ne manj kot 2,0 x 106 i.e.1, 2 rotaviruse tipa* P1A[8] ne manj kot 2,3 x 106 i.e.1, 2
Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinson’s disease and Restless Legs Syndrome.
Rotigotin je neergolinični agonist dopamina za zdravljenje znakov in simptomov Parkinsonove bolezni in sindroma nemirnih nog.
Rotigotine is believed to elicit its beneficial effect on Parkinson’s disease by activation of the D3, D2 and D1 receptors of the caudate-putamen in the brain.
Domneva se, da rotigotin doseže zdravilni učinek na Parkinsonovo bolezen doseže z aktivacijo receptorjev D3, D2 in D1 kavdatnega jedra ter putamena v možganih.
Rotigotine is believed to elicit its beneficial effect on Parkinson’s disease by activation of the D3, D2 and D1 receptors of the caudate-putamen in the brain.
Domneva se, da rotigotin doseže zdravilni učinek na Parkinsonovo bolezen z aktivacijo receptorjev D3, D2 in D1 kavdatnega jedra ter putamena v možganih.
Rotigotine is believed to elicit its beneficial effect on Parkinson’s disease by activation of the D3, D2 and D1 receptors of the caudate-putamen in the brain.
Domneva se, da rotigotin doseže zdravilni učinek na Parkinsonovo bolezenz aktivacijo receptorjev D3, D2 in D1 kavdatnega jedra ter putamena v možganih.
Rotigotine significantly reduced the periodic limb movement index (PLMI) from 50.9 to 7.7 versus 37.4 to 32.7 for placebo (p<0.0001).
Rotigotin je pomembno zmanjšal indeks periodičnega gibanja udov (Periodic Limb Movement Index - PLMI) iz 50,9 na 7,7 proti 37,4 na 32,7 za placebo (p<0,0001).
Rotigotine then stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as stiffness and slowness of movement.
Rotigotin zatem stimulira možgane enako kot dopamin, tako da lahko bolniki spet nadzirajo svoje gibe in kažejo manj znakov in simptomov Parkinsonove bolezni, kot so togost in počasnost gibov.
Round single-scored tablets
Okrogle tablete z zarezo na eni strani.
Round, beige film-coated tablet with “277” on one side.
Okrogla, sivorjava filmsko obložena tableta z oznako “277” na eni strani.
Round, biconvex, blue film-coated tablets.
Okrogle, bikonveksne, modre filmsko obložene tablete.
Round, biconvex, brown film-coated tablet (approximately 10.3 mm in diameter) debossed with ‘GS UFU’ and ‘50’ on one side.
Okrogle, obojestransko izbočene, rjave filmsko obložene tablete s premerom približno 10,3 mm in oznakama ‘GS UFU’ in ’50’ na eni strani.
Round, biconvex, pink film-coated tablet (approximately 10.3 mm in diameter) debossed with ‘GS FFS’ and ‘75’ on one side.
Okrogle, obojestransko izbočene, rožnate filmsko obložene tablete s premerom približno 10,3 mm in oznakama ‘GS FFS’ in ’75’ na eni strani.
Round, biconvex, pink tablets marked with ‘60’ above ‘T’ on one side and plain on the other.
Okrogla, bikonveksna, rožnata tableta z oznako "60" nad "T" na eni strani in brez oznak na drugi strani.
Round, biconvex, white film-coated tablet (approximately 10.3 mm in diameter) debossed with ‘GS NX3’ and ‘25’ on one side.
Okrogle, obojestransko izbočene, bele filmsko obložene tablete s premerom približno 10,3 mm in oznakama ‘GS NX3’ in ‘25’ na eni strani.
Round, biconvex, white film-coated tablet (approximately 7.9 mm in diameter) debossed with ‘GS MZ1’ and ‘12.5’ on one side.
Okrogle, obojestransko izbočene, bele filmsko obložene tablete s premerom približno 7,9 mm in oznakama ‘GS MZ1’ in ’12.5’ na eni strani.
Round, biconvex, yellow tablets marked with ‘90’ above ‘T’ on one side and plain on the other.
Okrogla, bikonveksna rumena tableta z oznako "90" nad "T" na eni strani in brez oznak na drugi strani.
Round, brown, film-coated tablets with “16” debossed on one side.
Okrogle, rjave, filmsko obložene tablete, s "16" vtisnjeno na eni strani.
Round, dark-violet, film-coated tablets with “12” debossed on one side.
Okrogle, temno vijolične, filmsko obložene tablete, z "12" vtisnjeno na eni strani.
Round, dark-yellow, film-coated tablets with “14” debossed on one side.
Okrogle, temno rumene, filmsko obložene tablete, s "14" vtisnjeno na eni strani.
Round, green, film-coated tablets with “8” debossed on one side.
Okrogle, zelene, filmsko obložene tablete, z "8" vtisnjeno na eni strani.
Round, light beige film-coated tablet with “112” on one side.
okrogla, svetlo sivorjava filmsko obložena tableta z oznako “112” na eni strani
Round, light beige film-coated tablet with “112”on one side.
Okrogla, svetlo sivorjava filmsko obložena tableta z oznako “112” na eni strani.
Round, light-yellow, film-coated tablets with “2” debossed on one side.
Okrogle, svetlo rumene, filmsko obložene tablete, z "2" vtisnjeno na eni strani.
Round, orange, film-coated tablets with “10” debossed on one side.
Okrogle, oranžne, filmsko obložene tablete, z "10" vtisnjeno na eni strani.
Round, pink film-coated tablet with “221” on one side.
okrogla, rožnata filmsko obložena tableta z oznako “221” na eni strani
Round, red, film-coated tablets with “4” debossed on one side.
Okrogle, rdeče, filmsko obložene tablete, s "4" vtisnjeno na eni strani.
Round, white to off-white, sublingual tablets debossed with “5” on one side.
Okrogle, bele do sivo-bele podjezične tablete z vtisnjeno oznako “5” na eni strani.
Round, white to off-white, sublingual tablets debossed with ”10” on one side.
Okrogle, bele do sivo-bele podjezične tablete z vtisnjeno oznako “10” na eni strani.
Round, white, biconvex tablet of 5.5 mm, 7 mm, 9 mm and 12 mm.
Okrogla, bela, bikonveksna tablete velikosti 5,5 mm, 7 mm, 9 mm in 12 mm.
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4112”.
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4112”.
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4115”.
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4115”.
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4116”.
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4116”.
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4117”.
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4117”.
Roundworm
glista
Roundworm Skin worm
c.) glista kožna glista
Roundworm Skin worm
glista kožna glista
Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina and Trichuris vulpis).
Preprečevanje infestacij zrazličnimi vrstami glist (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina and Trichuris vulpis).
Roundworms (Nematodes):
Valjasti črvi (Nematodi)
Roundworms (Nematodes):
Valjasti črvi (nematodi):
Roundworms:
Valjasti črvi:
route
odmerkov
Route
Pot uporabe
Route and method of administration
Metoda in postopek dajanja zdravila
Route and method of administration
Pot(i) in način uporabe
Route and method of administration
Pot(i) in način uporabe zdravila
Route de Belleville - Lieu-dit Maillard 01400 Châtillon-sur-Chalaronne France
Route de Belleville - Lieu-dit Maillard 01400 Châtillon-sur-Chalaronne Francija
Route of
EU/1/15/1051/002
Route of
Na in uporabe
Route of
Na in uporabe zdrčavila
Route of
Nacin uporabe
Route of
Način dajanja
Route of
Način uporabe
Route of
Način uporabe zdravila
Route of
Načina
Route of
Pot
Route of
Pot uporabe
Route of
Pot uporabe zdravila
Route of
uporabe
Route of Administ- ration
Pot uporabe
Route of administratio n
Pot uporabe
Route of administration
intramuskularna uporaba
ROUTE OF ADMINISTRATION
NAČIN IN POT(I) UPORABE
Route of administration
Način porabe
Route of administration
Način uporabe zdravila:
Route of Administration
pakiranja
Route of administration
pipeta z navojno
Route of administration
Pot dajanja
Route of administration
Pot uporaba
Route of administration
Pot uporabe Ovojnina Vsebina
Route of Administration
Pot uporabe Stična ovojnina Velikost
ROUTE OF ADMINISTRATION
POT(I) UPORABE
ROUTE OF ADMINISTRATION
POT(I) UPORABE ZDRAVILA
Route of administration
Poti dajanja
Route of Administration
ubkutana uporaba
Route of Administration Intravenous use
za intravensko uporabo
Route of administration Oral use
peroralna uporaba
Route of Administration Oral use
Pot uporabe
Route of Administration Subcutaneous
Subkutana uporaba
Route of Administration Subcutaneous use
Pot uporabe zdravila
ROUTE(S) OF ADMINISTRATION
NAČIN UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION
NAČINI UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE
ROUTE(S) OF ADMINISTRATION
POT UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION
POT(I) UPORABE
ROUTE(S) OF ADMINISTRATION
POT(I) UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION
POT(I) UPORABE ZUDRAVILA
Route:
Pot uporabe:
ROUTES OF ADMINISTRATION
POT(I) UPORABE ZDRAVILA
ROUTES OF ADMINISTRATION
POTI UPORABE
ROUTES OF ADMINISTRATION
POTI UPORABE ZDRAVILA
Routine assessment of this event should include complete blood counts and physical examination.
Rutinsko ocenjevanje tega učinka mora obsegati celotno krvno sliko in klinični pregled.
Routine laboratory tests may commonly reveal changes to liver functions (hyperbilirubinaemia including increased conjugated bilirubin, increased unconjugated blood bilirubin, increased blood bilirubin) as well as changes in blood count (e.g.
Rutinski laboratorijski testi lahko pogosto odkrijejo spremembe delovanja jeter (hiperbilirubinemija, vključno s povečanimi vrednostmi konjugiranega bilirubina, povečanimi vrednostmi nekonjugiranega bilirubina v krvi, povečanimi vrednostmi bilirubina v krvi) kot tudi spremembe v krvni sliki (npr.
Routine monthly pregnancy tests must be performed during this time.
V tem času morate redno vsak mesec opravljati teste nosečnosti.
Routine prevention of angioedema attacks
Preprečevanje napadov angioedema
Routine prevention of angioedema attacks in adults and adolescents 12 to 17 years old with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Preprečevanje napadov angioedema pri odraslih in mladostnikih, starih 12 do 17 let, s hudimi in ponavljajočimi se napadi dednega angioedema (HAE), ki ne prenašajo peroralnih zdravil za preprečevanje ali jih ta zdravila ne zaščitijo dovolj, ali pri bolnikih, pri katerih ponavljajoče se akutno zdravljenje ne zadostuje.
Routine reversal – deep neuromuscular blockade:
Rutinska prekinitev živčnomišične blokade – globoka živčnomišična blokada:
Routine reversal – moderate neuromuscular blockade:
Rutinska prekinitev živčnomišične blokade - zmerna živčnomišična blokada:
Routine risk minimisation activities
zmanjšanje tveganja
ROUTINE USE
VSAKODNEVNA UPORABA
Routine Use Follow these instructions for each injection
Vsakodnevna uporaba Za vsako injiciranje sledite naslednjim navodilom
Royal Docks London E16 2QJ United Kingdom
Royal Docks London E16 2QJ Velika Britanija
Royal Docks London E16 2QJ United Kingdom.
Royal Docks London E16 2QJ Velika Britanija.
RP > 1.15 * Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ..............
RP > 1,15* Inaktivirana bakterija Erysipelothrix rhusiopathiae, sev R32E11 .ELISA > 3,34 log2 IE50
RP inhibition
OATP1B/BCR
RP ≥ 1
RP* ≥ 1
RPED and RVO may occur with dabrafenib in combination with trametinib.
Pri zdravljenju z dabrafenibom v kombinaciji s trametinibom lahko pride do odstopa mrežničnega pigmentnega epitelija (RPED) ali zapore mrežnične vene (RVO).
RPLS is uncommon (it affects less than 1 in 100 people).
RPLS je občasen neželeni učinek (pojavi se pri manj kot 1 od 100 bolnikov).
RR (Post-induction)
RR (po uvedbi)
RR (Post-induction) CR+nCR CR+nCR+PR % (95% CI)
CR+nCR+PR% (95% CI)
RR (Post-transplant) CR+nCR CR+nCR+PR % (95%
CR+nCR+PR% (95% CI)
RR (Post-transplant) CR+nCR CR+nCR+PR % (95% CI)
CR+nCR+PR% (95% CI)
RR (Post-transplant)b
RR (po presaditvi)b
RR-MS, SP-MS and single clinical event suggestive of MS
RR-MS, SP-MS in enkratni demielinizacijski dogodek, ki nakazuje multiplo sklerozo
RR-MS, SP-MS and single clinical event suggestive of MS
RRMS, SPMS in enkratni demielinizacijski dogodek, ki nakazuje multiplo sklerozo
RR: 0.79 [0.67;0.93]
(257/275)
RR: 0.82 [0.68;0.99]
(331/404)
RR: 0.82 [0.68;0.99]
RT: 0,82 [0,68;0,99]
RR: 0.89 [0.83; 0.96]
RT: 0,82 [0,33;2,00]
RR: 1.06 [0.92;1.23]
(255/274)
RR: 1.06 [0.92;1.23]
RT: 1,06 [0,92;1,23]
RRR-α-tocopherol
(RRR)-α-tokoferol
RRR-α-tocopherol
Ostale sestavine:
RRR-α-tocopherol Beta-carotene Maize oil Propylene glycol
(RRR)-α-tokoferol Betakaroten Koruzno olje Propilenglikol
RRRa (%) (95% CI)
RRRa (%) (95 % IZ)
RSG - Rosiglitazone monotherapy; RSG + MET - Rosiglitazone with metformin; RSG + SU - Rosiglitazone with sulphonylurea; RSG + MET + SU - Rosiglitazone with metformin and sulphonylurea
RSG - rosiglitazon kot samostojno zdravilo; RSG + MET - rosiglitazon z metforminom; RSG + SU - rosiglitazon s sulfonilsečnino; RSG + MET + SU - rosiglitazon z metforminom in sulfonilsečnino
RT-PCR tools could be used in outbreak situations to differentiate between the vaccine virus genome and those of fields strains based on sequences unique to the CP7_E2alf.
V primeru izbruha bolezni bi se na podlagi edinstvenosti sekvenc za CP7_E2alf, za razlikovanje med virusnim genomom iz cepiva in tistimi iz izoliranih sevov na terenu lahko uporabilo RT-PCR diagnostično metodo.
RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109).
RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v PB, brez bolezni zunaj kostnega mozga, razen v vranici in jetrih (samo za 0102 in 0109).
RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver.
RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v
RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver.
RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v PB, brez bolezni zunaj kostnega mozga, razen v vranici in jetrih